The Staying Power of Small Molecules
October 8, 2026
We asked the 2026 Power List whether newer modalities have eclipsed small molecules – and where the traditional mainstay still wins
4 min read
False
October 8, 2026
We asked the 2026 Power List whether newer modalities have eclipsed small molecules – and where the traditional mainstay still wins
4 min read
By Andres Sirulnik
October 5, 2026
Regeneron's L. Andres Sirulnik explains why modernizing clinical trials is as important as developing new medicines
4 min read
October 2, 2026
We asked the 2026 Power List how the pharmaceutical industry can prepare for geopolitical, economic, regulatory, and scientific uncertainty
5 min read
October 1, 2026
Cellares Co-Founder and CEO discusses why the future of cell therapy depends on rethinking how therapies are made
3 min read
September 28, 2026
Renee Aguiar-Lucander argues that faster clinical trials and more pragmatic regulation are essential to bringing medicines to patients sooner
2 min read
September 22, 2026
CCRM CEO Michael May on quantum computing, commercialization, and the next era of cell therapy
5 min read
September 17, 2026
What one policy change would accelerate progress in drug development and manufacturing? We asked the 2026 Power List.
8 min read
September 15, 2026
The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics
4 min read
By Ali Tavassoli
September 10, 2026
Ali Tavassoli explains how cyclic peptides and new discovery tools are opening up once-inaccessible biology
8 min read
By Miguel Forte
September 8, 2026
Scientific progress alone isn't enough, says Miguel Forte, who argues that reimbursement and patient access will shape the next decade of cell and gene therapy
4 min read
False
False
False
Affiliations:
Specialties:
Areas of Expertise: